STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #785 by analyst upside · 2026-06-27
ZVRA
Zevra Therapeutics, Inc.
Healthcare · Market Cap $799M · P/E 6.6x
ANALYST PRICE TARGET
+106.3%
implied upside to consensus target
Current Price $13.52
Consensus Target $27.89
Bull Target $35.0
Bear Target $21.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
7
Hold
0
Sell
0
52-Week Low $7.16
52-Week High $14.27
YTD Return +62.1%
FUNDAMENTALS
Market Cap $799M
P/E Ratio (TTM) 6.6x
Forward P/E 11.3x
EPS (TTM) $2.06
PEG Ratio 10.67
Dividend Yield N/A
Revenue (TTM) $122M
Profit Margin 101.6%
52-WEEK RANGE
52-Week Low $7.16
52-Week High $14.27
Current Price $13.52
Bear Target $21.0
Bull Target $35.0
● Now $13.52 ● Target $27.89
TRADING DATA
Avg Volume 1.5M
YTD Return +62.1%
Analyst Count 9
Consensus Buy
Upside to Target +106.3%
Last Updated 2026-06-27

ANALYST SUMMARY

Zevra Therapeutics, Inc. (ZVRA) is currently trading at $13.52 with a Wall Street consensus price target of $27.89, implying potential upside of 106.3% over the next 12 months. 9 analysts currently cover ZVRA, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $35.0, while the most cautious has a target of $21.0.

ZVRA operates in the Healthcare sector with a market capitalisation of $799M. The stock is up 62.1% year-to-date and is currently trading near the upper end of its 52-week range of $7.16 – $14.27.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ZVRA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity — Reiterated
Buy → Buy 2026-06-11 Building track record
Maxim Group — Reiterated
Buy → Buy 2026-06-10 28% win rate (40 calls)
Guggenheim — Reiterated
Buy → Buy 2026-06-10 62% win rate (8 calls)
BTIG reit
Buy → Buy 2026-06-09 38% win rate (8 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2026-06-09 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-06-09 Building track record
Cantor Fitzgerald — Reiterated
Overweight → Overweight 2026-06-08 40% win rate (10 calls)
Guggenheim — Reiterated
Buy → Buy 2026-05-08 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
54
out of 100
Coverage depth
18/30
Consensus clarity
9/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →